Announcements

  • OSD onCAR-T: Preclinical Assessment of Potential for Secondary Malignancies - Clinical

    ๐Ÿ“… Date: Monday, June 16, 2025

    ๐Ÿ•› Time: 12:00 PM โ€“ 1:00 PM Eastern Time

    ๐Ÿ“ Location: Virtual Seminar @ https://global.gotomeeting.com/join/271724949

    ๐Ÿงช OSD Overview

    Join us for an engaging 1-hour discussion featuring:

    Dr. Gabriela Hernandez Hoyos (BMS) and Dr. Ilayaraja Muthuramu (J&J)
    Experts in genomic risk analysis and safety assessments of CAR T platforms

    They will explore:

    โ—        Genomic risks in lentiviral vs. gene-edited CAR T products

    โ—        Key molecular and functional assays used in risk assessment

    โ—        Preclinical safety challenges in autologous vs. allogeneic approaches

    โ—        Insights from published case studies and FDA-approved testing strategies

    ๐Ÿง  Who Should Attend?

    Scientists, researchers, and professionals working in:
    - Gene and cell therapy
    - Regulatory science
    - Oncology R&D
    - Translational medicine

    ๐Ÿ”— Why Attend?

    - Hear from leaders in the field
    - Participate in an open discussion on safety assessment strategies
    - Gain insights into regulatory and translational approaches for CAR T therapies